1. Home
  2. NXTC vs NERV Comparison

NXTC vs NERV Comparison

Compare NXTC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXTC
  • NERV
  • Stock Information
  • Founded
  • NXTC 2015
  • NERV 2007
  • Country
  • NXTC United States
  • NERV United States
  • Employees
  • NXTC N/A
  • NERV N/A
  • Industry
  • NXTC Biotechnology: Pharmaceutical Preparations
  • NERV Biotechnology: Pharmaceutical Preparations
  • Sector
  • NXTC Health Care
  • NERV Health Care
  • Exchange
  • NXTC Nasdaq
  • NERV Nasdaq
  • Market Cap
  • NXTC 13.9M
  • NERV 12.6M
  • IPO Year
  • NXTC 2019
  • NERV 2014
  • Fundamental
  • Price
  • NXTC $0.45
  • NERV $1.72
  • Analyst Decision
  • NXTC Strong Buy
  • NERV Hold
  • Analyst Count
  • NXTC 2
  • NERV 1
  • Target Price
  • NXTC $3.50
  • NERV $5.00
  • AVG Volume (30 Days)
  • NXTC 346.6K
  • NERV 12.0K
  • Earning Date
  • NXTC 07-31-2025
  • NERV 08-05-2025
  • Dividend Yield
  • NXTC N/A
  • NERV N/A
  • EPS Growth
  • NXTC N/A
  • NERV N/A
  • EPS
  • NXTC N/A
  • NERV 0.83
  • Revenue
  • NXTC N/A
  • NERV N/A
  • Revenue This Year
  • NXTC N/A
  • NERV N/A
  • Revenue Next Year
  • NXTC N/A
  • NERV N/A
  • P/E Ratio
  • NXTC N/A
  • NERV $2.08
  • Revenue Growth
  • NXTC N/A
  • NERV N/A
  • 52 Week Low
  • NXTC $0.22
  • NERV $1.15
  • 52 Week High
  • NXTC $1.82
  • NERV $3.50
  • Technical
  • Relative Strength Index (RSI)
  • NXTC 44.08
  • NERV 49.83
  • Support Level
  • NXTC $0.45
  • NERV $1.62
  • Resistance Level
  • NXTC $0.49
  • NERV $1.88
  • Average True Range (ATR)
  • NXTC 0.06
  • NERV 0.09
  • MACD
  • NXTC -0.01
  • NERV -0.01
  • Stochastic Oscillator
  • NXTC 0.74
  • NERV 52.06

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Share on Social Networks: